

(FILE 'HOME' ENTERED AT 20:34:16 ON 18 DEC 2002)

FILE 'AGRICOLA, ALUMINIUM, ANABSTR, APOLLIT, AQUIRE, BABS, BIOCOMMERCE, BIOTECHNO, CABA, CAOLD, CAPLUS, CBNB, CEABA-VTB, CEN, CERAB, CIN, COMPENDEX, CONFSCI, COPPERLIT, CORROSION, ENCOMPLIT, ENCOMPLIT2, FEDRIP, GENBANK, INSPEC, INSPHYS, INVESTEXT, IPA, ...' ENTERED AT 20:34:25 ON 18 DEC 2002

L1 752015 (AZIDO(2A)DEOXYTHYMID?) OR (DEOXY(2A)AZIDOTHYMID?) OR (DEOXY(2A)
L2 23012 (DIDEOXY(4A)DIDEHYDRO(4A)THYMID?) OR (DIDEOXY(2A)DIDEHYDROTHYMI
L3 135095 PACLITAXEL OR PLAXICEL OR TAXOL OR TAXAN? OR YEWTAXAN OR 33069-
L4 3577 (L1 OR 30516-87-1 OR L2) AND L3
L5 65 L4 AND (TELOMERE OR TELOMERASE)
L6 61 DUP REM L5 (4 DUPLICATES REMOVED)
L7 6 L6 NOT PY>=1999

=> d 17 total ibib abs

L7 ANSWER 1 OF 6 FEDRIP COPYRIGHT 2002 NTIS

ACCESSION NUMBER: 2002:145799 FEDRIP
NUMBER OF REPORT: CRISP 3R01CA77091-03S1
RESEARCH TITLE: **TELOMERES, TELOMERASE, AND**
CHEMOTHERAPY

STAFF: Principal Investigator: AU, JESSIE L; OHIO STATE UNIV
COLL OF PHARM, 500 W 12TH AVE, COLUMBUS, OH 43210
PERFORMING ORGN: OHIO STATE UNIVERSITY, COLUMBUS, OHIO
SUPPORTING ORGN: Supported By: NATIONAL CANCER INSTITUTE
FISCAL YEAR: 2001
FUNDING: Supplement (Type 3)
FILE SEGMENT: National Institutes of Health

SUM **Telomeres** are critical to the maintenance of chromosomal integrity and replication potential. Defective **telomeres** result in fused chromosomes and a block in chromosome separation during mitosis, while a loss of telomeric DNA sequences below an apparent lower threshold coincides with cell senescence. On the other hand, addition of telomeric repeats to chromosome breakpoints leads to chromosome healing. The elongation of **telomeres** is regulated by its length and is mediated by **telomerase**, an enzyme which is also induced by chromosome fragmentation. In the absence of **telomerase**, each cell division leads to loss of telomeric repeats because DNA polymerase cannot replicate the end of linear DNA molecules. The newly universal presence of **telomerase** in tumor cells and its infrequent presence in somatic cells suggests that **telomerase** inhibition may result in selective antitumor activity. However, the current belief is that **telomerase** inhibitors do not have significant antitumor activity, because **telomere** shortening due to **telomerase** inhibition occurs slowly (e.g. 40% shortening after 70 doublings in human B cells) and because cell replication can continue until the pre-existing **telomeres** are decreased to the critical minimum length. For example, cell death due to silencing of **telomerase** occurs only after 23-26 doublings. This application proposes to study the effects of anticancer drugs on **telomere**, and to determine whether **telomere** integrity and **telomerase** play a role in drug activity.

L7 ANSWER 2 OF 6 PROMT COPYRIGHT 2002 Gale Group

ACCESSION NUMBER: 1998:196858 PROMT
TITLE: Bristol-Myers Squibb Reports Record First Quarter Sales and Earnings
SOURCE: PR Newswire, (21 Apr 1998) pp. 0421NYTU013.
LANGUAGE: English

18/12/2002 20:52

WORD COUNT:

2006

FULL TEXT IS AVAILABLE IN THE ALL FORMAT

AB NEW YORK, April 21 /PRNewswire/ -- Bristol-Myers Squibb Company (NYSE: BMY) today reported record sales and earnings for the first quarter ended March 31, 1998.

"The results this quarter highlight the continuing strength and vitality of many of our key product franchises around the world," said Charles A. Heimbold, Jr., chairman and chief executive officer. "We saw excellent growth across the pharmaceutical and beauty care segments of the company. The U.S. marketplace is particularly vibrant, with strong trends for PRAVACHOL, GLUCOPHAGE, SERZONE, BUSPAR and TAXOL. Many of our other key pharmaceutical products also increased sales at double digit rates. At the same time, our beauty and personal care businesses -- with Clairol at the lead -- are extending their reach across the globe with successful hair care brands like HERBAL ESSENCES and DAILY DEFENSE. Bristol-Myers Squibb is widely recognized for the balance and strength of its businesses. The solid performance of the first quarter is evidence of a great product portfolio and superior execution in the marketplace." Sales for the first quarter grew 10% (14% excluding the effect of foreign exchange) to \$4.4 billion from \$4.0 billion in 1997. Domestic sales increased 16%, and international sales increased 2% (11% excluding the effect of foreign exchange).

The consolidated sales growth resulted from a 12% increase due to volume, a 2% increase due to changes in selling prices and a 4% decrease due to foreign exchange rate fluctuations. Excluding the effect of foreign exchange, beauty care sales increased 30%, pharmaceutical sales increased 17%, nutritional sales increased 6%, consumer medicines sales increased 1% and medical devices sales decreased 3%. Excluding the divestiture in December 1997 of Zimmer's arthroscopy and surgical powered instrument business, medical devices sales increased 11%.

THIS IS AN EXCERPT: COPYRIGHT 1998 PR Newswire Association, Inc.

L7 ANSWER 3 OF 6 CANCERLIT
ACCESSION NUMBER: 96653319 CANCERLIT
DOCUMENT NUMBER: 96653319
TITLE: Recent developments in the prevention and treatment of
 ovarian cancer: an overview (Meeting abstract).
AUTHOR: Kieback D G
CORPORATE SOURCE: Department of Obstetrics and Gynecology, Baylor College of
 Medicine, 6550 Fannin, Houston, TX 77030.
SOURCE: Anticancer Res, (1995) 15 (5A) 1764.
 ISSN: 0250-7005.
DOCUMENT TYPE: (MEETING ABSTRACTS)
LANGUAGE: English
FILE SEGMENT: Institute for Cell and Developmental Biology
ENTRY MONTH: 199609
ENTRY DATE: Entered STN: 19970509
 Last Updated on STN: 19970509

AB Ovarian cancer is the gynecologic cancer with the highest mortality. During the last several years, significant advances have been made in risk determination, surgical therapy, and chemotherapy. Important inroads have also been made regarding gene therapy of ovarian cancer. The recent discovery of the BRCA1 gene proved the existence of an autosomal dominant inheritance pattern of breast and ovarian cancer based on point mutations causing dysfunction in this large greater than 20 kb protein. No 'hot spots' for mutations have been identified thus far, making the individual diagnosis complicated and expensive. Since only 5% of individuals with ovarian cancer have a conclusive family history, the need for risk markers of sporadic disease is great. p53PIN3 and aberrations such as PROGINs in the progesterone receptor gene show promise in this regard. In ovarian cancer treatment, radical surgical removal of the primary tumor is crucial

to improve prognosis. CUSA surgery and stapling techniques for bowel resections and reanastomosis provide increased options for radical surgery without increasing patient risk. The array of prognostic factors and the understanding of tumor growth may be broadened by including revised modes of interpretation of estrogen receptor status and research in the area of orphan steroid receptors such as COUP-TF. Also, p53 mutations may play a role in this context. Postoperative chemotherapy is shifting towards a first line combination of **Taxol** and cisplatin as recent data indicate a 108 survival advantage with combined therapy. Second line treatment is problematic. Angiogenesis inhibitors, metallocenes and **telomerase** inhibitors are under investigation. There is presently clinical promise regarding gene therapy in the context of high-dose chemotherapy, where the MDR gene is transfected into bone marrow cells ex vivo. The bone marrow is reinfused and dose intensity for **Taxol** can be increased due to bone marrow resistance. In vivo gene therapy will be available to patients in the near future. Vector systems are adenoviruses, adenoassociated viruses and **retroviruses**. Research efforts are directed at intratumoral transfection of suicide genes, tumor suppressor genes and immune mediators. Advances in the treatment of chemotherapy side effects are serotonin antagonists against nausea and growth factors against leukopenia where crossreactivity with tumor promoting mechanisms may have to be considered in the choice of the bone marrow stimulant.

L7 ANSWER 4 OF 6 USPATFULL

ACCESSION NUMBER: 1998:128079 USPATFULL
 TITLE: Methods for generating and screening novel metabolic pathways
 INVENTOR(S): Thompson, Katie A., Del Mar, CA, United States
 Foster, Lyndon M., Carlsbad, CA, United States
 Peterson, Todd C., Chula Vista, CA, United States
 Nasby, Nicole Marie, San Diego, CA, United States
 Brian, Paul, San Diego, CA, United States
 PATENT ASSIGNEE(S): Chromaxome Corporation, San Diego, CA, United States
 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5824485		19981020
APPLICATION INFO.:	US 1996-639255		19960424 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1995-427244, filed on 25 Apr 1995, now abandoned And Ser. No. US 1995-427348, filed on 25 Apr 1995, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Ketter, James		
ASSISTANT EXAMINER:	Brusca, John S.		
NUMBER OF CLAIMS:	45		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	25 Drawing Figure(s); 21 Drawing Page(s)		
LINE COUNT:	4343		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a novel drug discovery system for generating and screening molecular diversity. The system provides methods for mixing and cloning genetic materials from a plurality of species of organisms in combinatorial gene expression libraries to generate novel metabolic pathways and classes of compounds. The system also involves methods for pre-screening or identifying for host organisms containing a library that are capable of generating such novel pathways and compounds. The host organisms may be useful in drug screening for particular diseases, and in commercial production of

compounds of interest. The methods of the invention are also useful in preserving the genomes of organisms that are known or prospective sources of drugs.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 5 OF 6 USPATFULL

ACCESSION NUMBER: 1998:98932 USPATFULL
TITLE: DHA-pharmaceutical agent conjugates of **taxanes**
INVENTOR(S): Shashoua, Victor E., Brookline, MA, United States
Swindell, Charles S., Merion, PA, United States
Webb, Nigel L., Bryn Mawr, PA, United States
Bradley, Matthews O., Laytonsville, MD, United States
PATENT ASSIGNEE(S): Neuromedica, Inc., Conshohocken, PA, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5795909		19980818
APPLICATION INFO.:	US 1996-651312		19960522 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Jarvis, William R. A.		
LEGAL REPRESENTATIVE:	Wolf, Greenfield & Sacks, P.C.		
NUMBER OF CLAIMS:	12		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	27 Drawing Figure(s); 14 Drawing Page(s)		
LINE COUNT:	2451		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides conjugates of cis-docosahexaenoic acid and **taxanes** useful in treating cell proliferative disorders.
Conjugates of **paclitaxel** and docetaxel are preferred.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 6 OF 6 USPATFULL

ACCESSION NUMBER: 1998:85814 USPATFULL
TITLE: Methods for generating and screening novel metabolic pathways
INVENTOR(S): Peterson, Todd C., Chula Vista, CA, United States
Foster, Lyndon M., Carlsbad, CA, United States
Brian, Paul, San Diego, CA, United States
PATENT ASSIGNEE(S): Chromaxome Corporation, San Diego, CA, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5783431		19980721
APPLICATION INFO.:	US 1996-738944		19961024 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1996-639255, filed on 24 Apr 1996		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Ketter, James		
ASSISTANT EXAMINER:	Brusca, John S.		
LEGAL REPRESENTATIVE:	Pennie & Edmonds LLP		
NUMBER OF CLAIMS:	25		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	27 Drawing Figure(s); 23 Drawing Page(s)		
LINE COUNT:	4805		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a novel drug discovery system for generating and screening molecular diversity. The system provides methods for mixing and cloning genetic materials from a plurality of species of organisms in combinatorial gene expression libraries to generate novel metabolic pathways and classes of compounds. The system also provides mobilizable combinatorial gene expression libraries that can be transferred from one species of host organism to another for expression. Also provided are specialized cloning vectors for making mobilizable gene expression libraries. The system also involves methods for pre-screening or identifying for host organisms containing a library that are capable of generating such novel pathways and compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

(FILE 'AGRICOLA, ALUMINIUM, ANABSTR, APOLLIT, AQUIRE, BABS, BIOCOMMERCE, BIOTECHNO, CABA, CAOLD, CAPLUS, CBNB, CEABA-VTB, CEN, CERAB, CIN, COMPENDEX, CONFSCI, COPPERLIT, CORROSION, ENCOMPLIT, ENCOMPLIT2, FEDRIP, GENBANK, INSPEC, INSPHYS, INVESTEXT, IPA, ...' ENTERED AT 20:57:44 ON 18 DEC 2002)

L8 1341 L2 AND L3
L9 17 L8 AND (TELOMERE OR TELOMERASE)
L10 14 DUP REM L9 (3 DUPLICATES REMOVED)

=> d l10 total ibib abs

L10 ANSWER 1 OF 14 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 1
ACCESSION NUMBER: 2002:521462 CAPLUS
DOCUMENT NUMBER: 137:88442
TITLE: Incensole and furanogermacrens and compounds in treatment for inhibiting neoplastic lesions and microorganisms
INVENTOR(S): Shanahan-Pendergast, Elisabeth
PATENT ASSIGNEE(S): Ire.
SOURCE: PCT Int. Appl., 68 pp.
CODEN: PTXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
WO 2002053138	A2	20020711	WO 2002-IE1	20020102
WO 2002053138	A3	20020919		
W:	AE, AG, AT, AU, BB, BG, CA, CH, CN, CO, CU, CZ, LU, LV, MA, MD, UA, UG, US, VN, YU, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, AT, BE, CH, CY, DE, ES, FI, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: IE 2001-2 A 20010102

OTHER SOURCE(S): MARPAT 137:88442

AB The invention discloses the use of incensole and/or furanogermacrens, derivs. metabolites and precursors thereof in the treatment of neoplasia, particularly resistant neoplasia and immunodysregulatory disorders. These compds. can be administered alone or in combination with conventional chemotherapeutic, antiviral, antiparasite agents, radiation and/or surgery. Incensole and furanogermacren and their mixture showed antitumor activity against various human carcinomas and melanomas and antimicrobial activity against Staphylococcus aureus and Enterococcus faecalis.

L10 ANSWER 2 OF 14 USPATFULL
ACCESSION NUMBER: 2002:315123 USPATFULL
TITLE: Fatty alcohol drug conjugates
INVENTOR(S): Swindell, Charles S., Merion, PA, UNITED STATES
Fegley, Glenn J., Eagleville, PA, UNITED STATES

	NUMBER	KIND	DATE
	-----	---	-----
PATENT INFORMATION:	US 2002177609	A1	20021128
APPLICATION INFO.:	US 2002-107537	A1	20020325 (10)

	NUMBER	DATE
	-----	-----
PRIORITY INFORMATION:	US 2001-278457P	20010323 (60)
DOCUMENT TYPE:	Utility	

18/12/2002 20:59

FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Edward R. Gates, Esq., Chantal Morgan D'Apuzzo, Wolf,
Greenfield & Sacks, P.C., 600 Atlantic Ave, Boston, MA,
02210
NUMBER OF CLAIMS: 136
EXEMPLARY CLAIM: 1
LINE COUNT: 2864

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides conjugates of fatty alcohols and pharmaceutical
agents useful in treating cancer, viruses, psychiatric disorders.
Compositions, pharmaceutical preparations, and methods of preparation of
the fatty alcohols-pharmaceutical agent conjugates are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 3 OF 14 USPATFULL

ACCESSION NUMBER: 2002:149299 USPATFULL
TITLE: Death domain-containing receptor polynucleotides,
polypeptides, and antibodies
INVENTOR(S): Ni, Jian, Germantown, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002077458	A1	20020620
APPLICATION INFO.:	US 2001-835788	A1	20010417 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2000-US28666, filed on 17 Oct 2000, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-159585P	19991018 (60)
	US 1999-167246P	19991124 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	22	
EXEMPLARY CLAIM:	1	
LINE COUNT:	14143	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel human DDCR polypeptides and
isolated nucleic acids containing the coding regions of the genes
encoding such polypeptides. Also provided are vectors, host cells,
antibodies, and recombinant methods for producing human DDCR
polypeptides. The invention further relates to diagnostic and
therapeutic methods useful for diagnosing and treating disorders related
to these novel human DDCR polypeptides.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 4 OF 14 USPATFULL

ACCESSION NUMBER: 2002:17328 USPATFULL
TITLE: Dha-pharmaceutical agent conjugates of **taxanes**
INVENTOR(S): Shashoua, Victor, Brookline, MA, UNITED STATES
Swindell, Charles, Merion, PA, UNITED STATES
Webb, Nigel, Bryn Mawr, PA, UNITED STATES
Bradley, Matthews, Layton, PA, UNITED STATES

NUMBER	KIND	DATE
-----	-----	-----

PATENT INFORMATION: US 2002010208 A1 20020124
APPLICATION INFO.: US 2001-846838 A1 20010501 (9)
RELATED APPLN. INFO.: Continuation of Ser. No. US 1998-135291, filed on 17
Aug 1998, ABANDONED Continuation of Ser. No. US
1996-651312, filed on 22 May 1996, GRANTED, Pat. No. US
5795909
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Edward R. Gates, Esq., Wolf, Greenfield & Sacks, P.C.,
600 Atlantic Avenue, Boston, MA, 02210
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 14 Drawing Page(s)
LINE COUNT: 2437

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides conjugates of cis-docosahexaenoic acid and
pharmaceutical agents useful in treating noncentral nervous system
conditions. Methods for selectively targeting pharmaceutical agents to
desired tissues are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 5 OF 14 USPATFULL

ACCESSION NUMBER: 2002:95605 USPATFULL
TITLE: Evolution of whole cells and organisms by recursive
sequence recombination
INVENTOR(S): del Cardayre, Stephen, Belmont, CA, United States
Tobin, Matthew, San Jose, CA, United States
Stemmer, Willem P. C., Los Gatos, CA, United States
Minshull, Jeremy, Menlo Park, CA, United States
PATENT ASSIGNEE(S): Maxygen, Inc., Redwood City, CA, United States (U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6379964	B1	20020430
APPLICATION INFO.:	US 1999-354922		19990715 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 116188		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-35054P	19970117 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Whisenant, Ethan	
LEGAL REPRESENTATIVE:	Kruse, Norman J., Quine, Jonathon Alan, The Law Offices of Jonathan Alan Quine	
NUMBER OF CLAIMS:	23	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	38 Drawing Figure(s); 41 Drawing Page(s)	
LINE COUNT:	7147	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides methods employing iterative cycles of
recombination and selection/screening for evolution of whole cells and
organisms toward acquisition of desired properties. Examples of such
properties include enhanced recombinogenicity, genome copy number, and
capacity for expression and/or secretion of proteins and secondary
metabolites.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 6 OF 14 USPATFULL

ACCESSION NUMBER: 2002:45499 USPATFULL

TITLE: Evolution of whole cells and organisms by recursive sequence recombination

INVENTOR(S): delCardayre, Stephen, Los Gatos, CA, United States
Tobin, Matthew, San Jose, CA, United States
Stemmer, William P. C., Los Gatos, CA, United States
Ness, Jon E., Sunnyvale, CA, United States
Minshull, Jeremy, Menlo Park, CA, United States
Patten, Phillip, Mountain View, CA, United States
Subramanian, Venkiteswatan, Danville, CA, United States
Castle, Linda, Mountain View, CA, United States
Krebber, Claus M., Mountain View, CA, United States
Bass, Steve, Hillsborough, CA, United States
PATENT ASSIGNEE(S): Maxygen, Inc., Redwood City, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6352859	B1	20020305
APPLICATION INFO.:	US 2000-626343		20000726 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 116188		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-35054P	19970117 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Fredman, Jeffrey	
ASSISTANT EXAMINER:	Chakrabarti, Arun Kr.	
LEGAL REPRESENTATIVE:	Kruse, Norman J., Quine, Jonathan Alan, Law Offices of Jonathan Alan Quine	
NUMBER OF CLAIMS:	6	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	35 Drawing Figure(s); 35 Drawing Page(s)	
LINE COUNT:	5542	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides methods employing iterative cycles of recombination and selection/screening for evolution of whole cells and organisms toward acquisition of desired properties. Examples of such properties include enhanced recombinogenicity, genome copy number, and capacity for expression and/or secretion of proteins and secondary metabolites.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 7 OF 14 USPATFULL

ACCESSION NUMBER: 2002:1103 USPATFULL

TITLE: Evolution of whole cells and organisms by recursive sequence recombination

INVENTOR(S): delCardayre, Stephen, Los Gatos, CA, United States
Tobin, Matthew, San Jose, CA, United States

PATENT ASSIGNEE(S): Maxygen, Inc., Redwood City, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6335198	B1	20020101
APPLICATION INFO.:	US 2000-626047		20000726 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1998-116188, filed on 15 Jul 1998 Continuation-in-part of Ser. No. WO 1998-US852,		

filed on 16 Jan 1998

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-35054P	19970107 (60)
	US 1997-35054P	19970107 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Whisenant, Ethan	
LEGAL REPRESENTATIVE:	Kruse, Norman J., Quine, Jonathan Alan, Law Office of Jonathan Alan Quine	
NUMBER OF CLAIMS:	49	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	35 Drawing Figure(s); 35 Drawing Page(s)	
LINE COUNT:	5654	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides methods employing iterative cycles of recombination and selection/screening for evolution of whole cells and organisms toward acquisition of desired properties. Examples of such properties include enhanced recombinogenicity, genome copy number, and capacity for expression and/or secretion of proteins and secondary metabolites.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 8 OF 14 USPATFULL

ACCESSION NUMBER: 2001:90260 USPATFULL
TITLE: Fatty acid-pharmaceutical agent conjugates
INVENTOR(S): Webb, Nigel L., Bryn Mawr, PA, United States
Bradley, Matthews O., Laytonsville, MD, United States
Swindell, Charles S., Merion, PA, United States
Shashoua, Victor E., Brookline, MA, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001002404	A1	20010531
APPLICATION INFO.:	US 2000-730450	A1	20001205 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1996-651428, filed on 22 May 1996, ABANDONED		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Edward R. Gates, Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA, 02210		
NUMBER OF CLAIMS:	12		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	14 Drawing Page(s)		
LINE COUNT:	2511		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides conjugates of fatty acids and pharmaceutical agents useful in treating noncentral nervous system conditions. Methods for selectively targeting pharmaceutical agents to desired tissues are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 9 OF 14 USPATFULL

ACCESSION NUMBER: 2001:220889 USPATFULL
TITLE: Evolution of whole cells and organisms by recursive sequence recombination
INVENTOR(S): delCardayre, Stephen, Los Gatos, CA, United States
Tobin, Matthew, San Jose, CA, United States

18/12/2002 20:59

Stemmer, William P. C., Los Gatos, CA, United States
 Ness, Jon E., Sunnyvale, CA, United States
 Minshull, Jeremy, Menlo Park, CA, United States
 Patten, Phillip, Mountain View, CA, United States
 Subramanian, Venkiteswatan, Danville, CA, United States
 Castle, Linda, Mountain View, CA, United States
 Bass, Steve, Hillsborough, CA, United States
 PATENT ASSIGNEE(S): Maxygen, Inc., Redwood City, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6326204	B1	20011204
APPLICATION INFO.:	US 1998-116188		19980715 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 1998-US852, filed on 16 Jan 1998		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Whisenant, Ethan		
LEGAL REPRESENTATIVE:	Kruse, Norman J., Quine, Jonathan Alan Law Offices of Jonathan Alan Quine		
NUMBER OF CLAIMS:	49		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	35 Drawing Figure(s); 35 Drawing Page(s)		
LINE COUNT:	5175		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides methods employing iterative cycles of recombination and selection/screening for evolution of whole cells and organisms toward acquisition of desired properties. Examples of such properties include enhanced recombinogenicity, genome copy number, and capacity for expression and/or secretion of proteins and secondary metabolites.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 10 OF 14 USPATFULL

ACCESSION NUMBER: 2001:152770 USPATFULL
 TITLE: Evolution of whole cells and organisms by recursive sequence recombination
 INVENTOR(S): delCardayre, Stephen, Belmont, CA, United States
 Tobin, Matthew, San Jose, CA, United States
 Stemmer, Willem P. C., Los Gatos, CA, United States
 Ness, Jon E., Sunnyvale, CA, United States
 Minshull, Jeremy, Menlo Park, CA, United States
 Patten, Phillip, Menlo Park, CA, United States
 Subramanian, Venkiteswaran, San Diego, CA, United States
 Castle, Linda, Mountain View, CA, United States
 Krebber, Claus M., Mountain View, CA, United States
 Bass, Steven H., Hillsborough, CA, United States
 PATENT ASSIGNEE(S): Maxygen, Inc., Redwood City, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6287862	B1	20010911
APPLICATION INFO.:	US 2000-626410		20000726 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1998-116188, filed on 15 Jul 1998 Continuation-in-part of Ser. No. WO 1998-US852, filed on 16 Jan 1998		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-35054P	19970107 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Whisenant, Ethan	
LEGAL REPRESENTATIVE:	Kruse, Norman J., Quine, Jonathan Alan	The Law Offices of Jonathan Alan Quine
NUMBER OF CLAIMS:	48	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	35 Drawing Figure(s); 35 Drawing Page(s)	
LINE COUNT:	5146	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides methods employing iterative cycles of recombination and selection/screening for evolution of whole cells and organisms toward acquisition of desired properties. Examples of such properties include enhanced recombinogenicity, genome copy number, and capacity for expression and/or secretion of proteins and secondary metabolites.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 11 OF 14 USPATFULL

ACCESSION NUMBER: 2001:97699 USPATFULL
 TITLE: Evolution of whole cells and organisms by recursive sequence recombination
 INVENTOR(S): Tobin, Matthew, San Jose, CA, United States
 Stemmer, William P. C., Los Gatos, CA, United States
 Ness, Jon E., Sunnyvale, CA, United States
 Minshull, Jeremy, Menlo Park, CA, United States
 PATENT ASSIGNEE(S): Maxygen, Inc., Redwood City, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6251674	B1	20010626
APPLICATION INFO.:	US 2000-499505		20000207 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 116188		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-35054P	19970107 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Whisenant, Ethan	
LEGAL REPRESENTATIVE:	Kruse, Norman J., Quine, Jonathan Alan	The Law Offices of Jonathan Alan Quine
NUMBER OF CLAIMS:	5	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	35 Drawing Figure(s); 35 Drawing Page(s)	
LINE COUNT:	5013	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides methods employing iterative cycles of recombination and selection/screening for evolution of whole cells and organisms toward acquisition of desired properties. Examples of such properties include enhanced recombinogenicity, genome copy number, and capacity for expression and/or secretion of proteins and secondary metabolites.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 2
 ACCESSION NUMBER: 2000:880951 CAPLUS
 DOCUMENT NUMBER: 134:37011
 TITLE: Methods and compositions for modulating antitumor drug activity through **telomere** damage, agent identification method, and method for detecting **telomerase** activity
 INVENTOR(S): Au, Jessie L.-S.; Wientjes, Guillaume
 PATENT ASSIGNEE(S): USA
 SOURCE: PCT Int. Appl., 97 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000074667	A2	20001214	WO 2000-US15544	20000605
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 1999-137549P P 19990604

AB Methods and compns. are provided for modulating the activity of therapeutic agents for the treatment of a cancer by administering one or more agents that (either alone or in combination) induces **telomere** damage and inhibits **telomerase** activity in the cancer cell. The method initially uses, e.g., a **telomere** damage-inducing agent such as **paclitaxel**, and a **telomerase** inhibitory agent such as AZT. The invention also provides methods for identifying other agents with **telomere** damage-inducing activity and/or **telomerase** inhibitory activity (as well as and compns. having such activity), for use in the treatment of cancer.

L10 ANSWER 13 OF 14 PROMT COPYRIGHT 2002 Gale Group

ACCESSION NUMBER: 1998:196858 PROMT
 TITLE: Bristol-Myers Squibb Reports Record First Quarter Sales and Earnings
 SOURCE: PR Newswire, (21 Apr 1998) pp. 0421NYTU013.
 LANGUAGE: English
 WORD COUNT: 2006

FULL TEXT IS AVAILABLE IN THE ALL FORMAT

AB NEW YORK, April 21 /PRNewswire/ -- Bristol-Myers Squibb Company (NYSE: BMY) today reported record sales and earnings for the first quarter ended March 31, 1998.

"The results this quarter highlight the continuing strength and vitality of many of our key product franchises around the world," said Charles A. Heimbold, Jr., chairman and chief executive officer. "We saw excellent growth across the pharmaceutical and beauty care segments of the company. The U.S. marketplace is particularly vibrant, with strong trends for PRAVACHOL, GLUCOPHAGE, SERZONE, BUSPAR and **TAXOL**. Many of our other key pharmaceutical products also increased sales at double digit rates. At the same time, our beauty and personal care businesses -- with Clairol at the lead -- are extending their reach across the globe with

successful hair care brands like HERBAL ESSENCES and DAILY DEFENSE. Bristol-Myers Squibb is widely recognized for the balance and strength of its businesses. The solid performance of the first quarter is evidence of a great product portfolio and superior execution in the marketplace." Sales for the first quarter grew 10% (14% excluding the effect of foreign exchange) to \$4.4 billion from \$4.0 billion in 1997. Domestic sales increased 16%, and international sales increased 2% (11% excluding the effect of foreign exchange).

The consolidated sales growth resulted from a 12% increase due to volume, a 2% increase due to changes in selling prices and a 4% decrease due to foreign exchange rate fluctuations. Excluding the effect of foreign exchange, beauty care sales increased 30%, pharmaceutical sales increased 17%, nutritional sales increased 6%, consumer medicines sales increased 1% and medical devices sales decreased 3%. Excluding the divestiture in December 1997 of Zimmer's arthroscopy and surgical powered instrument business, medical devices sales increased 11%.

THIS IS AN EXCERPT: COPYRIGHT 1998 PR Newswire Association, Inc.

L10 ANSWER 14 OF 14 USPATFULL

ACCESSION NUMBER: 1998:98932 USPATFULL

TITLE: DHA-pharmaceutical agent conjugates of **taxanes**

INVENTOR(S): Shashoua, Victor E., Brookline, MA, United States
Swindell, Charles S., Merion, PA, United States
Webb, Nigel L., Bryn Mawr, PA, United States
Bradley, Matthews O., Laytonsville, MD, United States
PATENT ASSIGNEE(S): Neuromedica, Inc., Conshohocken, PA, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5795909		19980818
APPLICATION INFO.:	US 1996-651312		19960522 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Jarvis, William R. A.		
LEGAL REPRESENTATIVE:	Wolf, Greenfield & Sacks, P.C.		
NUMBER OF CLAIMS:	12		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	27 Drawing Figure(s); 14 Drawing Page(s)		
LINE COUNT:	2451		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides conjugates of cis-docosahexaenoic acid and **taxanes** useful in treating cell proliferative disorders. Conjugates of **paclitaxel** and docetaxel are preferred.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.